SHOULDER INNOVATIONS INC

Tansey Casey’s fresh 733‑share purchase of Shoulder Innovations signals insider confidence in its tech‑pivot, urging investors to re‑evaluate the stock’s undervaluation and potential upside.

Insider buys at Shoulder Innovations signal board confidence amid a tech pivot—watch RSU‑driven gains and partnership wins for a potential rebound.

Gilde Healthcare’s steady selling of Shoulder Innovations shares signals gradual dilution amid a 4% weekly slide – investors weigh long‑term resilience against shifting insider ownership.

Gilde Healthcare’s gradual sale of 7,338 shares of Shoulder Innovations reveals a cautious approach amid rising Q2 revenue and market volatility—track the trend for investor insight.

Gilde Healthcare’s recent sale of 110k SIII shares near $23 raises questions, yet a fresh buy‑back plan suggests long‑term upside. Discover what it means for investors.

Insider sales at SHOULDER INNOVATIONS show a planned, risk‑mitigated move by COO Matthew Fraser—not a bearish signal, but a cue to watch future filings and market sentiment.

CEO Ball Robert Joseph buys 10,000 shares at $2.48 on a capital‑raise, signaling confidence in Shoulder Innovations’ expansion and potential upside for investors.

Insider CFO buys 13,264 shares at $2.48, converting options to cash before a crucial board vote – signals confidence but raises volatility risks for investors.

CEO Robert Joseph’s $2.48 insider buy fuels confidence in Shoulder Innovations as the stock edges toward a rebound.